Ashley Gallagher

Angiotensin-converting enzyme inhibitors have been known to be more effective in decreasing the incidence of major adverse cardiac events for patients with diabetes.

Guselkumab is the first and only IL-23 inhibitor to demonstrate robust data as a fully subcutaneous regimen.

Patients often have anxiety about potential adverse effects, and experiencing adverse effects can affect patient adherence.

Selarsdi is interchangeable for all indications of ustekinumab, including treatment of psoriatic arthritis, plaque psoriasis, Crohn disease, and ulcerative colitis.

The use of electronic prescribing can also bridge the gap in clinical history, which can help pharmacists be aware of adverse drug reactions and medication interactions.

Vaccination changes serotype distribution from vaccine-type serotypes to nonvaccine-type serotypes.

The investigators of a study also found that patient satisfaction with long-acting injectable antiretroviral therapy was equally as high when comparing home and clinic administration.

Shingle vaccination is recommended for adults 50 years and older and for adults 19 years and older who have a weakened immune system due to disease therapy.

As pharmacy schools continue to deal with recruitment challenges, the pharmacy workforce has its own set of challenges, including interest in nontraditional roles.

The Inflation Reduction Act's drug price negotiations could lead to reimbursement complexities, potential pharmacy closures, and reduced patient access to medications, particularly specialty drugs.

Although the market is expected to continue to become more popular, compounding pharmacies will no longer be allowed to manufacture these medications, as shortages have been listed as resolved.

Through communication and reform, pharmacies will be able to make changes in order to continue to provide the best care to patients.

Through digital innovations, transparency, and accessibility, pharmacists can help meet patients where they are at to improve their health outcomes.

Glucagon-like peptide-1 medications are the fastest-growing class of medication and will continue to be prevalent as more indications, such as sleep apnea, are added.

From medication dispensers to comprehensive patient care advocates, pharmacists have never been more essential to the health care team and to patients in specialty care.

The role of the community pharmacist is beginning to expand into specialty pharmacy spaces to increase access and outcomes for patients.

The findings support the need for improved vaccination coverage to prevent the resurgence of previously eliminated infectious diseases in the United States.

However, the results show that there was an improvement of symptom scores, although they were not significant.

In a new survey, approximately one-third of respondents have heard that the MMR vaccine is more dangerous than being infected with the infection.

Investigators specifically analyze information on influenza and pneumococcal vaccinations.

This method supports improved, early detection for diabetes without relying on blood samples or complex procedures.

Further, the authors of the “Standards of Care in Diabetes 2025” highlighted the benefits of continuous glucose monitoring systems and recommend initiating these as soon as possible.

The authors emphasize the importance of multifaceted and team-based approaches to the management of diabetes.

Investigators find that orforglipron lowered A1c by an average of 1.3% to 1.6% from a baseline of 8% across 3 different dosages.

Crystal Hodge discusses being transparent about adverse effects of the MMR vaccine and educating patients about measles.

The approval is based on 2 phase 3 studies demonstrating reductions in itch severity and urticaria activity as a composite of itch and hives at 24 weeks.

Crystal Hodge discusses R naughts and the measures of how contagious measles is.

The recommendation includes patients 12 years and older traveling to a country where there is a chikungunya outbreak or where there is an elevated risk for US travelers.

Currently, the recommendation is for patients 75 years and older and those aged 60 to 74 years with an increased risk of severe respiratory syncytial virus.

The FDA approved Penmenvy in February 2025 for use in patients aged 10 to 25 years.